BRPI0514386B8 - bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais - Google Patents

bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais

Info

Publication number
BRPI0514386B8
BRPI0514386B8 BRPI0514386A BRPI0514386A BRPI0514386B8 BR PI0514386 B8 BRPI0514386 B8 BR PI0514386B8 BR PI0514386 A BRPI0514386 A BR PI0514386A BR PI0514386 A BRPI0514386 A BR PI0514386A BR PI0514386 B8 BRPI0514386 B8 BR PI0514386B8
Authority
BR
Brazil
Prior art keywords
pentoxy
phenoxy
isopropyl
hydroxy
methyl
Prior art date
Application number
BRPI0514386A
Other languages
English (en)
Inventor
Seok Jeon Chan
Hyuk Shin Dong
Hee Cho Eun
Man Ryu Jei
Soo Lee Jin
Young Lee Ki
Hyun Jung Se
Hoon Ahn Seok
Kyoo Seong Seung
Ki Cho Soon
Goo Jin Young
Original Assignee
Dong Wha Pharmaceutical Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514386(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharmaceutical Ind Co Ltd filed Critical Dong Wha Pharmaceutical Ind Co Ltd
Publication of BRPI0514386A publication Critical patent/BRPI0514386A/pt
Publication of BRPI0514386B1 publication Critical patent/BRPI0514386B1/pt
Publication of BRPI0514386B8 publication Critical patent/BRPI0514386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

sal do ácido n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina-2-meta-nossulfônico. a presente invenção refere-se a um sal do ácido de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina-2-meta-nossulfônico, que apresenta excelente biodisponibilidade. são também descritas um método de preparação do composto e uma composição farmacêutica contendo o composto.
BRPI0514386A 2004-11-23 2005-11-22 bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais BRPI0514386B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0096390 2004-11-23
KR20040096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (3)

Publication Number Publication Date
BRPI0514386A BRPI0514386A (pt) 2008-06-10
BRPI0514386B1 BRPI0514386B1 (pt) 2021-02-09
BRPI0514386B8 true BRPI0514386B8 (pt) 2021-05-25

Family

ID=36498212

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0517396-5A BRPI0517396A (pt) 2004-11-23 2005-11-22 preparação oral com melhor biodisponibilidade
BRPI0514386A BRPI0514386B8 (pt) 2004-11-23 2005-11-22 bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0517396-5A BRPI0517396A (pt) 2004-11-23 2005-11-22 preparação oral com melhor biodisponibilidade

Country Status (19)

Country Link
US (2) US20070254930A1 (pt)
EP (2) EP1701722B1 (pt)
JP (2) JP4773456B2 (pt)
KR (2) KR101047042B1 (pt)
CN (3) CN100574756C (pt)
AT (1) ATE445397T1 (pt)
AU (2) AU2005307994B2 (pt)
BR (2) BRPI0517396A (pt)
CA (2) CA2585003C (pt)
DE (1) DE602005017118D1 (pt)
DK (1) DK1701722T3 (pt)
ES (1) ES2333739T3 (pt)
HK (1) HK1094530A1 (pt)
IL (2) IL180985A (pt)
NZ (1) NZ555725A (pt)
PT (1) PT1701722E (pt)
RU (1) RU2361867C2 (pt)
WO (2) WO2006057507A1 (pt)
ZA (2) ZA200700485B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
ATE445397T1 (de) * 2004-11-23 2009-10-15 Dong Wha Pharm Co Ltd N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz
CA2684582C (en) * 2007-04-19 2012-05-29 Dong Wha Pharmaceutical Co. Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical compositioncomprising the same
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RS58433B1 (sr) † 2011-07-28 2019-04-30 Rigel Pharmaceuticals Inc Nove formulacije (trimetoksifenilamino)pirimidinila
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6680297B2 (ja) 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SG11202001436YA (en) * 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
TW201912157A (zh) 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
WO1989006959A1 (en) * 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
NZ518581A (en) * 1999-10-28 2004-11-26 Sankyo Co Benzamidine derivatives
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
ATE541575T1 (de) * 2002-03-06 2012-02-15 Effrx Pharmaceuticals Sa Brausetabletten, enthaltend alendronat
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
JP4669391B2 (ja) * 2003-03-18 2011-04-13 興和株式会社 制酸剤組成物
ATE445397T1 (de) * 2004-11-23 2009-10-15 Dong Wha Pharm Co Ltd N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz

Also Published As

Publication number Publication date
ATE445397T1 (de) 2009-10-15
EP1814593A1 (en) 2007-08-08
AU2005307994B2 (en) 2009-07-23
DK1701722T3 (da) 2010-01-11
HK1094530A1 (en) 2007-04-04
CN1905871A (zh) 2007-01-31
CN100574756C (zh) 2009-12-30
ES2333739T3 (es) 2010-02-26
KR100716389B1 (ko) 2007-05-11
BRPI0514386B1 (pt) 2021-02-09
IL182647A0 (en) 2007-07-24
US20070254930A1 (en) 2007-11-01
JP2008508264A (ja) 2008-03-21
CA2585003A1 (en) 2006-06-01
ZA200704236B (en) 2008-11-26
BRPI0517396A (pt) 2008-10-14
WO2006057501A1 (en) 2006-06-01
DE602005017118D1 (de) 2009-11-26
EP1701722B1 (en) 2009-10-14
EP1701722A1 (en) 2006-09-20
RU2007123614A (ru) 2008-12-27
EP1701722A4 (en) 2007-05-16
PT1701722E (pt) 2009-12-10
KR20060057514A (ko) 2006-05-26
CA2552766A1 (en) 2006-06-01
CN101693029B (zh) 2011-11-02
CN101056658A (zh) 2007-10-17
AU2005300239A1 (en) 2006-07-06
KR20060057511A (ko) 2006-05-26
CA2585003C (en) 2010-08-17
IL182647A (en) 2011-04-28
JP4774053B2 (ja) 2011-09-14
KR101047042B1 (ko) 2011-07-06
CA2552766C (en) 2010-08-17
IL180985A (en) 2012-02-29
CN1905871B (zh) 2010-07-07
NZ555725A (en) 2008-07-31
CN101693029A (zh) 2010-04-14
JP4773456B2 (ja) 2011-09-14
US20090176846A1 (en) 2009-07-09
JP2008520655A (ja) 2008-06-19
BRPI0514386A (pt) 2008-06-10
IL180985A0 (en) 2007-07-04
WO2006057507A1 (en) 2006-06-01
ZA200700485B (en) 2007-11-28
RU2361867C2 (ru) 2009-07-20
AU2005307994A1 (en) 2006-06-01
AU2005300239B2 (en) 2009-08-06
EP1814593A4 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
IL182647A0 (en) An oral preparation having improved bioavailability
CL2008002142A1 (es) Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares.
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
WO2012147107A3 (en) Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
MA34897B1 (fr) Formulations d'immunosupresseurs
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
NO20063662L (no) Benzimidazolderivater
UA92354C2 (en) Amino acid salts of rosiglitazone
AR051754A1 (es) Metodos para preparar compuestos de indazol
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
RU2007134564A (ru) Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
ATE523498T1 (de) Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate
EP4162937A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF PARKINSON'S DISEASE, COMPRISING A COMPOUND OF THE TYPE 2-(4-(1-HYDROXYPROPANE-2-YL)PHENYL)ISOINDOLIN-1-ONE
DOP2006000240A (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil)-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparación del mismo
JP2006523626A5 (pt)
AR029657A1 (es) Compuesto derivado de sulfonil piperidina o piperazina, composicion farmaceutica que lo comprende, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por enzimas metaloproteinasas y procesos para su preparacion
BRPI0518613A2 (pt) compostos, composiÇço farmacÊutica, mÉtodo de preparar uma composiÇço, e, uso de um composto
NO20075766L (no) Aminoalkyl-amidometyl-substituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater og deres anvendelse som kaliumkanalblokkere
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF